vs
Side-by-side financial comparison of EXPONENT INC (EXPO) and USANA HEALTH SCIENCES INC (USNA). Click either name above to swap in a different company.
USANA HEALTH SCIENCES INC is the larger business by last-quarter revenue ($250.2M vs $166.3M, roughly 1.5× EXPONENT INC). EXPONENT INC runs the higher net margin — 17.8% vs 3.0%, a 14.8% gap on every dollar of revenue. On growth, EXPONENT INC posted the faster year-over-year revenue change (14.3% vs -3.0%). Over the past eight quarters, USANA HEALTH SCIENCES INC's revenue compounded faster (11.8% CAGR vs 8.8%).
Exponent, Inc. is an American engineering and scientific consulting firm. Exponent has a team of scientists, physicians, engineers, and business consultants which performs research and analysis in more than 90 technical disciplines. The company operates 20 offices in the United States and five offices overseas.
Usana Health Sciences, Inc., or USANA, is an American multi-level marketing company based in Salt Lake City, Utah. As of 2021, Usana was the 14th largest direct-selling company in the world by revenue. The company manufactures most of its nutritional products, dietary supplements, and skincare products at a Salt Lake City facility. Its products are sold in 24 countries via a network of independent distributors.
EXPO vs USNA — Head-to-Head
Income Statement — Q1 FY2027 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $166.3M | $250.2M |
| Net Profit | $29.6M | $7.5M |
| Gross Margin | — | 76.2% |
| Operating Margin | 24.9% | 5.5% |
| Net Margin | 17.8% | 3.0% |
| Revenue YoY | 14.3% | -3.0% |
| Net Profit YoY | 11.0% | -20.0% |
| EPS (diluted) | $0.59 | $0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $166.3M | $250.2M | ||
| Q4 25 | $147.1M | $226.2M | ||
| Q3 25 | $142.0M | $213.7M | ||
| Q2 25 | $145.5M | $235.8M | ||
| Q1 25 | $136.8M | $249.5M | ||
| Q4 24 | — | $213.6M | ||
| Q3 24 | $136.3M | $200.2M | ||
| Q2 24 | $140.5M | — |
| Q1 26 | $29.6M | $7.5M | ||
| Q4 25 | $28.0M | $180.0K | ||
| Q3 25 | $26.6M | $-6.5M | ||
| Q2 25 | $26.6M | $9.7M | ||
| Q1 25 | $23.6M | $9.4M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | $26.0M | $10.6M | ||
| Q2 24 | $29.2M | — |
| Q1 26 | — | 76.2% | ||
| Q4 25 | — | 78.2% | ||
| Q3 25 | — | 77.2% | ||
| Q2 25 | — | 78.7% | ||
| Q1 25 | — | 79.0% | ||
| Q4 24 | — | 82.0% | ||
| Q3 24 | — | 80.4% | ||
| Q2 24 | — | — |
| Q1 26 | 24.9% | 5.5% | ||
| Q4 25 | 19.7% | 1.7% | ||
| Q3 25 | 12.1% | 0.6% | ||
| Q2 25 | 30.5% | 7.1% | ||
| Q1 25 | 19.9% | 6.3% | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | 19.0% | 7.8% | ||
| Q2 24 | 25.4% | — |
| Q1 26 | 17.8% | 3.0% | ||
| Q4 25 | 19.1% | 0.1% | ||
| Q3 25 | 18.7% | -3.1% | ||
| Q2 25 | 18.3% | 4.1% | ||
| Q1 25 | 17.2% | 3.8% | ||
| Q4 24 | — | 2.1% | ||
| Q3 24 | 19.1% | 5.3% | ||
| Q2 24 | 20.8% | — |
| Q1 26 | $0.59 | $0.41 | ||
| Q4 25 | $0.55 | $-0.10 | ||
| Q3 25 | $0.52 | $-0.36 | ||
| Q2 25 | $0.52 | $0.52 | ||
| Q1 25 | $0.45 | $0.49 | ||
| Q4 24 | — | $0.23 | ||
| Q3 24 | $0.50 | $0.56 | ||
| Q2 24 | $0.57 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $118.6M | $162.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $338.3M | — |
| Total Assets | $687.4M | $739.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $118.6M | $162.8M | ||
| Q4 25 | $207.4M | $158.4M | ||
| Q3 25 | $231.8M | $145.3M | ||
| Q2 25 | $245.1M | $151.3M | ||
| Q1 25 | $258.9M | $179.6M | ||
| Q4 24 | — | $181.8M | ||
| Q3 24 | $219.7M | $364.9M | ||
| Q2 24 | $203.3M | — |
| Q1 26 | $338.3M | — | ||
| Q4 25 | $402.9M | — | ||
| Q3 25 | $427.8M | $528.1M | ||
| Q2 25 | $441.4M | $531.1M | ||
| Q1 25 | $421.1M | $529.8M | ||
| Q4 24 | — | $532.1M | ||
| Q3 24 | $410.3M | $533.1M | ||
| Q2 24 | $393.2M | — |
| Q1 26 | $687.4M | $739.0M | ||
| Q4 25 | $761.4M | $742.9M | ||
| Q3 25 | $759.4M | $726.6M | ||
| Q2 25 | $763.2M | $734.5M | ||
| Q1 25 | $777.3M | $746.6M | ||
| Q4 24 | — | $748.2M | ||
| Q3 24 | $744.1M | $671.3M | ||
| Q2 24 | $709.2M | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXPO
| Revenues before reimbursements | $151.8M | 91% |
| Reimbursements | $14.5M | 9% |
USNA
Segment breakdown not available.
